The effects of spironolactone and metoprolol on QT dispersion in patients with congestive heart failure

Basit Öğe Kaydı
dc.contributor.authorAkbulut, M
dc.contributor.authorKaraca, I
dc.contributor.authorIlkay, E
dc.contributor.authorÖzbay, Y
dc.contributor.authorArslan, N
dc.date.accessioned2026-08-12T17:01:39Z
dc.date.issued2001
dc.departmentFırat Üniversitesi
dc.description4th International Congress on Coronary Artery Disease -- OCT 21-24, 2001 -- PRAGUE, CZECH REPUBLIC
dc.description.abstractWe aimed to evaluate the effects of spironolactone and metaprolol on ejection fraction (EF), QT dispersion (QTd) and corrected QTd (QTdc) in ischemic heart failure. A total of 106 NHYA class II-III patients (mean age: 58.4+/-12 year; 46 female) were included in this study. The patients were followed for a total 12 weeks by 3 week periods. As a result, mean echocardiographic EF and NYHA functional capacity improved in all groups (p< 0.05). But, these improvements were not significant between groups (p>0.05). Shortening of QTd and QTdc in group-II and group-III were significant when compared with group-I (p:0.000, p:0.001). Spironolactone and metaprolol shortened mortality predictor QTd and QTdc beside their good effect on EF.
dc.identifier.endpage566
dc.identifier.startpage561
dc.identifier.urihttps://hdl.handle.net/11508/47824
dc.identifier.wosWOS:000174610000087
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherMedimond S R L
dc.relation.ispartofAdvances in Coronary Artery Disease
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectMortality
dc.subjectMorbidity
dc.subjectBlockade
dc.subjectTherapy
dc.subjectRisk
dc.titleThe effects of spironolactone and metoprolol on QT dispersion in patients with congestive heart failure
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu